• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

炎症性 CCRK 通路驱动肥胖相关肝细胞癌中 mTORC1 依赖性代谢和免疫抑制重编程。

An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma.

机构信息

Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.

Department of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.

出版信息

Nat Commun. 2018 Dec 6;9(1):5214. doi: 10.1038/s41467-018-07402-8.

DOI:10.1038/s41467-018-07402-8
PMID:30523261
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6283830/
Abstract

Obesity increases the risk of hepatocellular carcinoma (HCC) especially in men, but the molecular mechanism remains obscure. Here, we show that an androgen receptor (AR)-driven oncogene, cell cycle-related kinase (CCRK), collaborates with obesity-induced pro-inflammatory signaling to promote non-alcoholic steatohepatitis (NASH)-related hepatocarcinogenesis. Lentivirus-mediated Ccrk ablation in liver of male mice fed with high-fat high-carbohydrate diet abrogates not only obesity-associated lipid accumulation, glucose intolerance and insulin resistance, but also HCC development. Mechanistically, CCRK fuels a feedforward loop by inducing STAT3-AR promoter co-occupancy and transcriptional up-regulation, which in turn activates mTORC1/4E-BP1/S6K/SREBP1 cascades via GSK3β phosphorylation. Moreover, hepatic CCRK induction in transgenic mice stimulates mTORC1-dependent Gcsf expression to enhance polymorphonuclear myeloid-derived suppressor cell recruitment and tumorigenicity. Finally, the STAT3-AR-CCRK-mTORC1 pathway components are concordantly over-expressed in human NASH-associated HCCs. These findings unveil the dual roles of an inflammatory-CCRK circuitry in driving metabolic and immunosuppressive reprogramming through mTORC1 activation, thereby establishing a pro-tumorigenic microenvironment for HCC development.

摘要

肥胖增加了肝细胞癌(HCC)的风险,尤其是在男性中,但分子机制尚不清楚。在这里,我们表明雄激素受体(AR)驱动的癌基因细胞周期相关激酶(CCRK)与肥胖引起的促炎信号协同作用,促进非酒精性脂肪性肝炎(NASH)相关的肝癌发生。用高脂肪高碳水化合物饮食喂养的雄性小鼠肝脏中通过慢病毒介导的 Ccrk 基因敲除不仅消除了与肥胖相关的脂质积累、葡萄糖不耐受和胰岛素抵抗,还消除了 HCC 的发展。在机制上,CCRK 通过诱导 STAT3-AR 启动子共占据和转录上调来提供正反馈回路,这反过来又通过 GSK3β 磷酸化激活 mTORC1/4E-BP1/S6K/SREBP1 级联反应。此外,转基因小鼠肝脏中 CCRK 的诱导刺激 mTORC1 依赖性 Gcsf 表达,以增强多形核髓样来源的抑制性细胞的募集和致瘤性。最后,在人类 NASH 相关 HCC 中共同过度表达了 STAT3-AR-CCRK-mTORC1 通路成分。这些发现揭示了炎症-CCRK 通路在通过 mTORC1 激活驱动代谢和免疫抑制重编程中的双重作用,从而为 HCC 的发展建立了促肿瘤微环境。

相似文献

1
An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma.炎症性 CCRK 通路驱动肥胖相关肝细胞癌中 mTORC1 依赖性代谢和免疫抑制重编程。
Nat Commun. 2018 Dec 6;9(1):5214. doi: 10.1038/s41467-018-07402-8.
2
Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.肝癌内在 CCRK 抑制作用可减弱髓源抑制性细胞的免疫抑制作用,并增强免疫检查点阻断疗效。
Gut. 2018 May;67(5):931-944. doi: 10.1136/gutjnl-2017-314032. Epub 2017 Sep 22.
3
A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients.CCRK-EZH2 表观遗传电路驱动肝癌发生,并与肿瘤复发和患者不良生存相关。
J Hepatol. 2015 May;62(5):1100-11. doi: 10.1016/j.jhep.2014.11.040. Epub 2014 Dec 9.
4
Cell cycle-related kinase mediates viral-host signalling to promote hepatitis B virus-associated hepatocarcinogenesis.细胞周期相关激酶介导病毒-宿主信号转导促进乙型肝炎病毒相关肝癌发生。
Gut. 2014 Nov;63(11):1793-804. doi: 10.1136/gutjnl-2013-305584. Epub 2014 Jan 17.
5
Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives β-catenin/T cell factor-dependent hepatocarcinogenesis.细胞周期相关激酶是雄激素受体直接调控的基因,可驱动β-连环蛋白/T 细胞因子依赖性肝癌发生。
J Clin Invest. 2011 Aug;121(8):3159-75. doi: 10.1172/JCI45967. Epub 2011 Jul 11.
6
Bufalin inhibits hepatitis B virus-associated hepatocellular carcinoma development through androgen receptor dephosphorylation and cell cycle-related kinase degradation.蟾毒灵通过去磷酸化雄激素受体和降解细胞周期相关激酶抑制乙型肝炎病毒相关肝细胞癌的发展。
Cell Oncol (Dordr). 2020 Dec;43(6):1129-1145. doi: 10.1007/s13402-020-00546-0. Epub 2020 Jul 4.
7
Bufalin suppresses hepatocarcinogenesis by targeting β-catenin/TCF signaling via cell cycle-related kinase.蟾毒灵通过细胞周期相关激酶靶向β-连环蛋白/TCF 信号通路抑制肝癌发生。
Sci Rep. 2018 Mar 1;8(1):3891. doi: 10.1038/s41598-018-22113-2.
8
Persistent mTORC1 activation via Depdc5 deletion results in spontaneous hepatocellular carcinoma but does not exacerbate carcinogen- and high-fat diet-induced hepatic carcinogenesis in mice.通过缺失Depdc5持续激活mTORC1会导致小鼠自发性肝细胞癌,但不会加剧致癌物和高脂饮食诱导的肝脏致癌作用。
Biochem Biophys Res Commun. 2021 Nov 12;578:142-149. doi: 10.1016/j.bbrc.2021.09.036. Epub 2021 Sep 20.
9
CCRK is a novel signalling hub exploitable in cancer immunotherapy.CCRK 是一种新型的信号枢纽,可用于癌症免疫治疗。
Pharmacol Ther. 2018 Jun;186:138-151. doi: 10.1016/j.pharmthera.2018.01.008. Epub 2018 Mar 1.
10
Cell cycle-related kinase reprograms the liver immune microenvironment to promote cancer metastasis.细胞周期相关激酶重塑肝脏免疫微环境促进癌症转移。
Cell Mol Immunol. 2021 Apr;18(4):1005-1015. doi: 10.1038/s41423-020-00534-2. Epub 2020 Sep 2.

引用本文的文献

1
BQ323636.1 Employs the AR-CCRK Axis to Modulate the Expression of KU70 to Interfere with Non-Homologous End Joining Mediated DNA Repair Mechanism.BQ323636.1利用AR-CCRK轴调节KU70的表达,以干扰非同源末端连接介导的DNA修复机制。
Cells. 2025 Aug 29;14(17):1341. doi: 10.3390/cells14171341.
2
Non-Coding RNAs as Critical Modulators of Cholesterol Metabolism in Cancer.非编码RNA作为癌症中胆固醇代谢的关键调节因子
Biomedicines. 2025 Jul 3;13(7):1631. doi: 10.3390/biomedicines13071631.
3
The Role of Cholesterol Metabolism and Its Regulation in Tumor Development.

本文引用的文献

1
SK-Hep1: not hepatocellular carcinoma cells but a cell model for liver sinusoidal endothelial cells.SK-Hep1:并非肝癌细胞,而是肝窦内皮细胞的一种细胞模型。
Int J Clin Exp Pathol. 2018 May 1;11(5):2931-2938. eCollection 2018.
2
Downregulation of CPT2 promotes tumorigenesis and chemoresistance to cisplatin in hepatocellular carcinoma.CPT2的下调促进肝细胞癌的肿瘤发生及对顺铂的化疗耐药。
Onco Targets Ther. 2018 May 25;11:3101-3110. doi: 10.2147/OTT.S163266. eCollection 2018.
3
CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity.
胆固醇代谢及其调节在肿瘤发生中的作用。
Cancer Med. 2025 Apr;14(7):e70783. doi: 10.1002/cam4.70783.
4
Transfer learning radiomic model predicts intratumoral tertiary lymphoid structures in hepatocellular carcinoma: a multicenter study.迁移学习放射组学模型预测肝细胞癌瘤内三级淋巴结构:一项多中心研究
J Immunother Cancer. 2025 Mar 4;13(3):e011126. doi: 10.1136/jitc-2024-011126.
5
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease.细胞周期蛋白依赖性蛋白激酶与生物学和疾病中的细胞周期调控
Signal Transduct Target Ther. 2025 Jan 13;10(1):11. doi: 10.1038/s41392-024-02080-z.
6
From MASLD to HCC: What's in the middle?从代谢相关脂肪性肝病到肝细胞癌:中间环节是什么?
Heliyon. 2024 Jul 31;10(15):e35338. doi: 10.1016/j.heliyon.2024.e35338. eCollection 2024 Aug 15.
7
Sex-Dependent T Cell Dysregulation in Mice with Diet-Induced Obesity.饮食诱导肥胖小鼠中性别依赖性 T 细胞失调。
Int J Mol Sci. 2024 Jul 28;25(15):8234. doi: 10.3390/ijms25158234.
8
Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside.免疫抑制性肿瘤微环境在肝细胞癌进展、转移及治疗中的作用:从实验台到临床应用
Exp Hematol Oncol. 2024 Aug 1;13(1):72. doi: 10.1186/s40164-024-00539-x.
9
Impact of obesity‑associated myeloid‑derived suppressor cells on cancer risk and progression (Review).肥胖相关的髓系来源抑制细胞对癌症风险和进展的影响(综述)。
Int J Oncol. 2024 Aug;65(2). doi: 10.3892/ijo.2024.5667. Epub 2024 Jun 28.
10
Unraveling the intricate relationship between lipid metabolism and oncogenic signaling pathways.解析脂质代谢与致癌信号通路之间的复杂关系。
Front Cell Dev Biol. 2024 Jun 12;12:1399065. doi: 10.3389/fcell.2024.1399065. eCollection 2024.
CPT2 下调使 HCC 适应富含脂质的环境,并通过肥胖症中酰基辅酶 A 的积累促进癌变。
Gut. 2018 Aug;67(8):1493-1504. doi: 10.1136/gutjnl-2017-315193. Epub 2018 Feb 6.
4
CCRK is a novel signalling hub exploitable in cancer immunotherapy.CCRK 是一种新型的信号枢纽,可用于癌症免疫治疗。
Pharmacol Ther. 2018 Jun;186:138-151. doi: 10.1016/j.pharmthera.2018.01.008. Epub 2018 Mar 1.
5
Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.肠道圆桌会议论文:肝细胞癌近期的部分进展
Gut. 2018 Feb;67(2):380-388. doi: 10.1136/gutjnl-2017-315068. Epub 2017 Nov 17.
6
Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes.肿瘤浸润淋巴细胞凋亡介导的癌症免疫治疗抵抗。
Nat Commun. 2017 Nov 10;8(1):1404. doi: 10.1038/s41467-017-00784-1.
7
CDK20 inhibition and immune checkpoint blockade: bringing cancer biology and tumour immunology together to develop novel treatment options for HCC.细胞周期蛋白依赖性激酶20(CDK20)抑制与免疫检查点阻断:将癌症生物学与肿瘤免疫学相结合以开发肝癌的新型治疗方案。
Gut. 2018 May;67(5):783-784. doi: 10.1136/gutjnl-2017-315091. Epub 2017 Oct 24.
8
Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.肝癌内在 CCRK 抑制作用可减弱髓源抑制性细胞的免疫抑制作用,并增强免疫检查点阻断疗效。
Gut. 2018 May;67(5):931-944. doi: 10.1136/gutjnl-2017-314032. Epub 2017 Sep 22.
9
Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients.凝集素型氧化型低密度脂蛋白受体-1可区分癌症患者中人类多形核髓源性抑制细胞群体。
Sci Immunol. 2016 Aug;1(2). doi: 10.1126/sciimmunol.aaf8943. Epub 2016 Aug 5.
10
High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1.2 million men.青少年晚期高 BMI 预测未来严重肝脏疾病和肝细胞癌:一项针对 120 万男性的全国性、基于人群的队列研究。
Gut. 2018 Aug;67(8):1536-1542. doi: 10.1136/gutjnl-2016-313622. Epub 2017 Mar 20.